79 research outputs found
Cosmology with clusters of galaxies
In this Chapter I review the role that galaxy clusters play as tools to
constrain cosmological parameters. I will concentrate mostly on the application
of the mass function of galaxy clusters, while other methods, such as that
based on the baryon fraction, are covered by other Chapters of the book. Since
most of the cosmological applications of galaxy clusters rely on precise
measurements of their masses, a substantial part of my Lectures concentrates on
the different methods that have been applied so far to weight galaxy clusters.
I provide in Section 2 a short introduction to the basics of cosmic structure
formation. In Section 3 I describe the Press--Schechter (PS) formalism to
derive the cosmological mass function, then discussing extensions of the PS
approach and the most recent calibrations from N--body simulations. In Section
4 I review the methods to build samples of galaxy clusters at different
wavelengths. Section 5 is devoted to the discussion of different methods to
derive cluster masses. In Section 6 I describe the cosmological constraints,
which have been obtained so far by tracing the cluster mass function with a
variety of methods. Finally, I describe in Section 7 the future perspectives
for cosmology with galaxy clusters and the challenges for clusters to keep
playing an important role in the era of precision cosmology.Comment: 49 pages, 19 figures, Lectures for 2005 Guillermo Haro Summer School
on Clusters, to appear in "Lecture notes in Physics" (Springer
A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry
Although men of African ancestry have a high risk of prostate cancer (PCa), no genes or mutations have been identified that contribute to familial clustering of PCa in this population. We investigated whether the African ancestry–specific PCa risk variant at 8q24, rs72725854, is enriched in men with a PCa family history in 9052 cases, 143 cases from high-risk families, and 8595 controls of African ancestry. We found the risk allele to be significantly associated with earlier age at diagnosis, more aggressive disease, and enriched in men with a PCa family history (32% of high-risk familial cases carried the variant vs 23% of cases without a family history and 12% of controls). For cases with two or more first-degree relatives with PCa who had at least one family member diagnosed at age <60 yr, the odds ratios for TA heterozygotes and TT homozygotes were 3.92 (95% confidence interval [CI] = 2.13–7.22) and 33.41 (95% CI = 10.86–102.84), respectively. Among men with a PCa family history, the absolute risk by age 60 yr reached 21% (95% CI = 17–25%) for TA heterozygotes and 38% (95% CI = 13–65%) for TT homozygotes. We estimate that in men of African ancestry, rs72725854 accounts for 32% of the total familial risk explained by all known PCa risk variants. Patient summary: We found that rs72725854, an African ancestry–specific risk variant, is more common in men with a family history of prostate cancer and in those diagnosed with prostate cancer at younger ages. Men of African ancestry may benefit from the knowledge of their carrier status for this genetic risk variant to guide decisions about prostate cancer screening. © 2020 The AuthorsThe African ancestry–specific prostate cancer risk variant at 8q24, rs72725854, is enriched in men diagnosed at younger ages and men with a prostate cancer family history. Carriers of this risk allele would benefit from regular and earlier prostate cancer screening
Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry
Background: Genetic factors play an important role in prostate cancer (PCa) susceptibility. Objective: To discover common genetic variants contributing to the risk of PCa in men of African ancestry. Design, setting, and participants: We conducted a meta-analysis of ten genome-wide association studies consisting of 19 378 cases and 61 620 controls of African ancestry. Outcome measurements and statistical analysis: Common genotyped and imputed variants were tested for their association with PCa risk. Novel susceptibility loci were identified and incorporated into a multiancestry polygenic risk score (PRS). The PRS was evaluated for associations with PCa risk and disease aggressiveness. Results and limitations: Nine novel susceptibility loci for PCa were identified, of which seven were only found or substantially more common in men of African ancestry, including an African-specific stop-gain variant in the prostate-specific gene anoctamin 7 (ANO7). A multiancestry PRS of 278 risk variants conferred strong associations with PCa risk in African ancestry studies (odds ratios [ORs] >3 and >5 for men in the top PRS decile and percentile, respectively). More importantly, compared with men in the 40–60% PRS category, men in the top PRS decile had a significantly higher risk of aggressive PCa (OR = 1.23, 95% confidence interval = 1.10–1.38, p = 4.4 × 10–4). Conclusions: This study demonstrates the importance of large-scale genetic studies in men of African ancestry for a better understanding of PCa susceptibility in this high-risk population and suggests a potential clinical utility of PRS in differentiating between the risks of developing aggressive and nonaggressive disease in men of African ancestry. Patient summary: In this large genetic study in men of African ancestry, we discovered nine novel prostate cancer (PCa) risk variants. We also showed that a multiancestry polygenic risk score was effective in stratifying PCa risk, and was able to differentiate risk of aggressive and nonaggressive disease
Electrophysiological investigation of adenosine trisphosphate-sensitive potassium channels in the rat substantia nigra pars reticulata
Excitation of rat substantia nigra pars reticulata neurons by 5-hydroxytryptaminein vitro: Evidence for a direct action mediated by 5-hydroxytryptamine2C receptors
GABA-mediated changes in inter-hemispheric beta frequency activity in early-stage Parkinson’s disease
AbstractIn Parkinson’s disease (PD), elevated beta (15–35Hz) power in subcortical motor networks is widely believed to promote aspects of PD symptomatology, moreover, a reduction in beta power and coherence accompanies symptomatic improvement following effective treatment with l-DOPA. Previous studies have reported symptomatic improvements that correlate with changes in cortical network activity following GABAA receptor modulation. In this study we have used whole-head magnetoencephalography to characterize neuronal network activity, at rest and during visually cued finger abductions, in unilaterally symptomatic PD and age-matched control participants. Recordings were then repeated following administration of sub-sedative doses of the hypnotic drug zolpidem (0.05mg/kg), which binds to the benzodiazepine site of the GABAA receptor. A beamforming based ‘virtual electrode’ approach was used to reconstruct oscillatory power in the primary motor cortex (M1), contralateral and ipsilateral to symptom presentation in PD patients or dominant hand in control participants. In PD patients, contralateral M1 showed significantly greater beta power than ipsilateral M1. Following zolpidem administration contralateral beta power was significantly reduced while ipsilateral beta power was significantly increased resulting in a hemispheric power ratio that approached parity. Furthermore, there was highly significant correlation between hemispheric beta power ratio and Unified Parkinson’s Disease Rating Scale (UPDRS). The changes in contralateral and ipsilateral beta power were reflected in pre-movement beta desynchronization and the late post-movement beta rebound. However, the absolute level of movement-related beta desynchronization was not altered. These results show that low-dose zolpidem not only reduces contralateral beta but also increases ipsilateral beta, while rebalancing the dynamic range of M1 network oscillations between the two hemispheres. These changes appear to underlie the symptomatic improvements afforded by low-dose zolpidem
The interaction of recurrent axon collateral networks in the basal ganglia
We have proposed that the basal ganglia act as the central switching mechanism for the action selection system of the vertebrate brain. Simulation of our functional model of basal ganglia demonstrated that their output was consistent with this action selection hypothesis. Here we extend this model by incorporating anatomically-inspired local inhibitory axon collateral networks into two basal ganglia nuclei (globus pallidus and substantia nigra pars reticulata). Through simulation it is demonstrated that the basal ganglia’s ability to function as a selection mechanism is impaired by the individual addition of the collateral networks but slightly improved when they co-exist. Therefore, we predict the existence of local axon collaterals in the entopeduncular nucleus because of its functional equivalence with the substantia nigra pars reticulata.We conclude that the action selection hypothesis is supported by the continued functioning of the basal ganglia model as a switching mechanism following appropriate anatomically-inspired additions
Assessment of epileptogenic potential: experimental, clinical and epidemiological approaches
- …
